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Abstract 
Currently available screening tests for prostate cancer (PCa) are neither very sensitive nor 
specific. Microparticles (MP) are submicron tumor cell fragments released by PCa cells into 
the circulation and offer a possible means of sampling the tumor. We evaluated the utility of 
a MP blood test using nanoscale flow cytometry to distinguish patients with PCa from 
patients with benign prostatic hyperplasia (BPH). We used monoclonal antibodies against 
prostate specific membrane antigen, gastrin releasing peptide receptor and ghrelin peptide 
ligand.  
We found higher but statistically insignificant, PSMA and Ghrelin dual positive MP counts 
in the BPH group. Our results show that although MP can be enumerated, better more 
exclusive surface antigens and different antibodies are required to test the utility of MP for 
this to be used as a "Next Generation Screening Tool" for PCa. In addition, comparison with 
a more suitable control group would improve accuracy of the experimental test.  
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Chapter 1  
1 Introduction  
1.1 General Overview 
Prostate Cancer (PCa) is leading the list of all newly diagnosed visceral cancers in men, 
and each year it is responsible for approximately 9.3% of all cancer related deaths (Jemal 
et al. 2010). Currently, detection of PCa relies on a blood test known as Prostate Specific 
Antigen (PSA), digital rectal examination (DRE), and transrectal ultrasound guided 
biopsy (TRUS) of prostate. PCa is among the few solid organ malignancies which have a 
surrogate tumor marker to detect the disease and monitor its course. Although PSA is a 
highly sensitive and specific marker in the post treatment setting, especially post radical 
prostatectomy, it has a very low sensitivity and specificity as a screening tool. In 2011, 
the U.S. Preventive Services Task Force (USPSTF) drafted a recommendation against the 
routine use of PSA screening at any age and in October 2012 the USPSTF website posted 
that “Prostate cancer is a serious health problem that affects thousands of men and their 
families. But before getting a PSA test, all men deserve to know what the science tells us 
about PSA screening: there is a very small potential benefit and significant potential 
harms. We encourage clinicians to consider this evidence and not screen their patients 
with a PSA test unless the individual being screened understands what is known about 
PSA screening and makes the personal decision that even a small possibility of benefit 
outweighs the known risk of harms.” (USPSTF Co-Chair Michael LeFevre, M.D., 
M.S.P.H. May 22, 2012).  
 2 
 
A large prospective study from Europe Organization for Research and Treatment of 
Cancer (EORTC) looking at the role of PSA based screening program, ERSPC trial 
(European Randomised Study of Screening for Prostate Cancer) in reduction of mortality 
reported that a very large number of men need to be screened (1410 men) in order to save 
one life (Schroder et al. 2009). The Prostate, Lung, Colorectal and Ovarian Cancer 
(PLCO) Screening Trial, also investigating the usefulness of PSA as a screening tool, 
showed that the incidence of death per 10,000 person-years was 2.0 (50 deaths) in the 
PSA based screening group and 1.7 (44 deaths) in the control group (Andriole et al. 
2009). Both of these studies demonstrated only a small benefit with PSA based screening, 
thus underlining the point that PSA is not an ideal screening test. There is no absolute 
cutoff level defined for PSA based screening, with the majority of clinicians using the 
classic threshold of >4 mg/ml (Catalona et al. 1991). However, a large study looking at 
2950 men with PSA of < 4mg/ml found that 15.2% of men with PSA’s in this range were 
later found to have PCa (Thompson et al. 2004). Currently, based on “suspicious PSA”, 
almost one million men in the USA undergo prostate biopsy each year and are exposed to 
significant complications (Welsh et al. 2007). Prostate biopsy carries a risk of potential 
complications such as hematuria and urinary tract infections and is reported to have a 
6.9% hospitalization rate (Loeb et al. 2011). The current standard of performing a 
prostate biopsy is for systematic sampling of the prostate using TRUS guidance. 
Previously, only six cores (sextant) of prostate were obtained. However, this was found to 
be inadequate and today, most centers perform a 10-12 core biopsy. This scheme of 
biopsy has improved the detection rate to around 50% (Martinez et al. 2013).  Therefore, 
 3 
 
the majorities of men with suspicious PSA levels actually do not have PCa and are 
unnecessarily exposed to the risks of biopsy. 
To meet the challenge of developing a screening test superior to PSA, we propose a blood 
test based on prostate cancer microparticles (PCMP). Microparticles (MP) are submicron 
(< 1µm) particles released from cells during their growth, malignant transformation or 
apoptosis (Rak, 2013). MP are released in the circulation and express surface receptors 
inherited from their cells of origin (Andreu et al. 2014). We enumerated PCMP using a 
combination of monoclonal antibodies (mAb) namely prostate specific membrane 
antigen, gastrin releasing peptide receptor and ghrelin peptide ligand which have been 
shown to bind to the extracellular portion of the receptors inherited by the MP derived 
from the PCa cells. We used these PCMP counts to distinguish between plasmas from 
patients with localized PCa and benign prostatic hyperplasia (BPH). The MP based test 
has the potential of functioning as a “fluid biopsy” which can continually sample the 
primary tumor to gain insight regarding the biology of these tissues. 
 
1.2 Prostate Cancer 
Prostate cancer (PCa) accounts for 27% of all newly diagnosed visceral malignancies 
among men in the USA (Siegel et al. 2014). In 2014, it is estimated to affect 233,000 
men in the USA and will account for 10% of all male cancer related deaths in men 
(DeSantis et al. 2014). The Canadian Cancer Society estimates that 23,600 men will be 
diagnosed with PCa in 2014, representing 24% of all new cancer cases in men and nearly 
4,000 men will die from PCa in Canada.  This translates into 65 Canadian men being 
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diagnosed and approximately 11 men dying of PCa every day (www.cancer.ca). These 
statistics place prostate cancer as one of the leading cancers affecting males in North 
America. Prostate cancer typically has a long course, thus making it a major consumer of 
the health care budget.  Overall, the lifetime risk of developing PCa is about 16.7%; 
therefore one in six men will be diagnosed with prostate cancer in their life time. The 
incidence of harboring a focus of clinically insignificant PCa is even higher as autopsy 
studies performed on prostate glands obtained from men dying of all causes has shown 
that 20% of men aged 50 to 60 years and 50% of men, aged 70 to 80 years, have 
histologic evidence of carcinoma prostate (Carter et al. 1990). This disparity between 
clinically significant cancer and incidental or indolent cancer has led to numerous efforts 
to risk stratify this disease. None are perfect and study in this area is the major focus of 
prostate cancer research. Naturally, this uncertainty provokes a genuine anxiety among 
men at the risk of developing prostate cancer (Kotwal et al. 2012).  
The definitive reason for development of PCa is not yet known. However, there are 
several risk factors which increase the life-time risk of developing PCa. Risk factors 
include family history, ethnicity, diet, and environmental factors (Crawford, 2003). The 
risk of prostate cancer doubles among men having a first-degree relative with PCa and 
rises up to eightfold or greater if both a first and second degree relative previously had 
prostate cancer. Ethnicity is also a risk factor, as a wide variation in incidence has been 
reported between different ethnic groups. Table 1 shows the incidence and mortality of 
PCa among men in different ethnic populations (Campbell-Walsh Urology, tenth edition, 
2010). Asian men have the lowest mortality rates and highest incidence and mortality 
rates are observed in African–American men. Studies looking at the incidence of PCa 
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among immigrants, moving from an area of low incidence to higher incidence locations 
have reported significant increase in incidence of PCa in the immigrants compared to the 
natives in their country of origin. The increase in the incidence of PCa is more if 
immigration happened earlier in life of an individual. The higher incidence is also seen in 
the second generation of immigrants originating from areas of lower incidence.. This 
signifies the influence of environmental factors in development of cancers (Shimizu et al. 
1991). 
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Table 1. Incidence and mortality rate of prostate cancer in different ethnic groups 
(Adopted from Wein AJ, Kavoussi LR, Novick AC, Partin AW  & Peters CA, eds. 
Campbell-Walsh Urology, 10th Edition. Philadelphia: Saunders, 2010. 
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A high dietary intake of red meat, animal and polyunsaturated fats and milk appear to 
increase the risk of prostate cancer whereas, fruit and vegetables and polyphenols may be 
of preventive value for development of PCa. A review of dietary factors influencing the 
risk of PCa does not suggest any conclusive evidence to elucidate the role of the above 
agents in the development or prevention of PCa (Mandare et al. 2014). Anecdotal 
experiences and small nonrandomized studies have long promoted Selenium, Lycopene 
and Vitamin E as dietary supplements to prevent the development of PCa. To provide 
conclusive answer to this query a large prospective, multicenter study was designed. This 
Selenium, lycopene and Vitamin E Cancer Prevention Trial (SELECT) found no 
preventive effects of any of these substances in the development of prostate cancer (Klein 
et al. 2011). On the contrary, it provided some evidence that Vitamin E in high dose 
actually increased the risk of development of PCa. 
The prostate gland is a walnut-sized structure located at the bladder neck, and the urethra 
passes through the center of this gland. Figure 1 illustrates the anatomic location and 
relationship of prostate gland in a male pelvis (Campbell-Walsh Urology, tenth edition, 
2010). The function of the prostate gland relates to its secretory role that nourishes and 
protects sperm during insemination. As this gland is located just anterior to the rectum, it 
can be easily palpated during digital rectal examination.  
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Figure 1. Anatomical location of the prostate gland. The gland is shown in purple color 
lying at the base of the urinary bladder and just anterior to the rectum. Adopted from 
Wein AJ, Kavoussi LR, Novick AC, Partin AW  & Peters CA, eds. Campbell-Walsh 
Urology, 10th Edition. Philadelphia: Saunders, 2010. 
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Figure 2.  Zonal anatomy of prostate showing arrangement of zones of prostate. Adopted 
from Wein AJ, Kavoussi LR, Novick AC, Partin AW  & Peters CA, eds. Campbell-
Walsh Urology, 10th Edition. Philadelphia: Saunders, 2010. 
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McNeal, in his original description of the zonal anatomy of prostate gland, described four 
basic anatomic zones (McNeal, 1980). This description was further modified later and 
Figure 2 shows the current understanding of the zonal anatomy of the prostate gland 
(Campbell-Walsh Urology, tenth edition, 2010).  
Prostate carcinoma typically arises from the peripheral zone and cancer cells originate 
mainly from the secretory cells. Thus, prostate cancer is classified as ‘Acinar 
adenocarcinoma’. Histologically, prostate carcinoma can range from well-differentiated 
tumors which simulate normal prostatic glands, to poorly differentiated lesions which 
have completely lost the glandular architecture and cannot be easily recognized as 
descending from prostatic origin. A numeric grading system was introduced by Dr. 
Donald Gleason to grade the degree of loss of differentiation (Gleason, 1974). PCa 
exhibits a variety of histological patterns within a prostate cancer specimen. The Gleason 
grading system incorporates this unique characteristic, in which the most predominant 
pattern is called ‘Gleason Major’ and the second most common is called ‘Gleason 
Minor’. Gleason score, a sum of Gleason Major and Minor is assigned to pathological 
specimen incorporating both the patterns. This numeric score ranging from 2 to 10, out of 
a maximum of 10, is meant to reflect the histological pattern accounting for biological 
aggressiveness. The International Society of Urological Pathology made some 
modifications to this system in 2005 and this system is still prevalent in grading of PCa 
(Epstein et al. 2005). Table 2 illustrates the patterns with assignment of grades according 
to the 2005 Modification of International Society of Urological Pathologist (Campbell-
Walsh Urology, tenth edition, 2010). 
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Table 2.  Modified Gleason’s histological grading system Adopted from Wein AJ, 
Kavoussi LR, Novick AC, Partin AW  & Peters CA, eds. Campbell-Walsh Urology, 10th 
Edition. Philadelphia: Saunders, 2010. 
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Prostatic carcinoma can metastasize through lymphatic or hematogenous dissemination.  
Bone metastases are the most common site of hematogenous spread. Lymphatic 
metastases occur frequently to the obturator lymph nodes (Campbell-Walsh Urology, 
tenth edition, 2010).  
Prostate cancer is staged according to the guidelines of the 7th edition of American Joint 
Committee on Cancer (AJCC). This staging system is commonly referred to as TNM 
system. T stage refers to the volume of disease or the local extend of tumor, N reflects the 
lymph node status and M categorize the metastasis, if present. Clinical TNM stage based 
on local examination and imaging results is commonly referred to as cTNM. The 
pathological TNM or pTNM, however, is the final stage assigned after histological 
evaluation of the surgically removed prostate gland, along with regional lymph nodes. 
Table 3 illustrates the details of TNM staging system (Campbell-Walsh Urology, tenth 
edition, 2010). 
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Tx Primary Tumor could not be assessed 
T0 No evidence of Tumor 
T1 Tumor not palpable 
T2a Tumor palpable in less than half of one lobe 
T2b Tumor palpable in more than half of one lobe 
T2c Tumor palpable in both lobes 
Nx Nodal metastasis cannot be assessed 
N0 No nodal metastasis 
N1 Nodal metastasis in single node less than 2 cm 
N2 Nodal metastasis in single/multiple nodes less than 5 cm 
N3 Nodal metastasis in multiple nodes more than 5 cm 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1a Involvement of non regional lymph nodes 
M1b Involvement of bones 
M1c Involvement of other sites 
Table 3. Tumor staging (TNM) according AJCC 7th edition 
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In the last three decades there has been a migration in the stage at which PCa presents to 
the health care provider (Scosyrev et al. 2012). Most of the patients now present with 
asymptomatic and early stage cancer. Previously, a majority of patients were diagnosed 
with symptomatic bony metastasis or urinary obstruction. In the nineties, a blood test 
(PSA) was introduced in clinical practice that led to larger numbers of patients being 
diagnosed at an earlier and potentially curable stage. Prostate biopsy is now mostly 
recommended due to an abnormal PSA test. PSA is not a true tumor maker as such a 
marker should only be raised in a malignant condition but PSA may be elevated in a 
variety of other noncancerous prostate conditions. Interestingly, this PSA induced stage 
migration has had a very little impact on reducing the overall mortality of PCa. This 
observation led to the effort to critically appraise the role of PSA in reducing the 
mortality of PCa. In 2011, the U.S. Preventive Services Task Force (USPSTF) 
recommended against the routine use of PSA screening at any age. This recommendation 
was based mainly on the results of two large prospective studies demonstrating that a 
large number of men need to be screened (NNS) with PSA to detect PCa and prevent 
cancer related death. The EORTC study showed that 1410 men need to be screened and 
48 men needed to be treated (NNT) in order to prevent one death related to PCa 
(Schroder et al. 2009). Although, the recent publication of extended follow-up (13 years) 
of this cohort has shown improvement in the NNS (Schroder et al. 2014), PSA still does 
not fulfill any currently acceptable standards for an ideal screening test. Urgent efforts are 
required to develop a new screening test for detection of PCa.  
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1.3 Prostate Specific Antigen (PSA) 
PSA is a glycoprotein enzyme from the kallikrein-related peptidase family and is 
produced by prostatic epithelial cells. It is also known as gamma-seminoprotein or 
kallikrein-3 (KLK3). The physiological role is in the liquefaction of semen. It helps in 
dissolving the coagulum and allows the sperm to swim freely for insemination. 
Prostate specific antigen was first purified in humans in 1979 (Wang et al. 1979). Prior to 
this, prostate acid phosphatase (PAP) was used as a marker for PCa. PAP was non-
specific for prostate cancer and was elevated in a variety of other conditions like Paget’s 
disease. Prior to the establishment of PSA as a blood-based tumor marker, it was shown 
to be an exclusive immunohistologic marker for prostatic cancer. In an experiment using 
histological sections, it was observed that all sections from primary and metastatic 
prostatic cancer reacted positively with PSA, whereas non-prostatic neoplasms did not 
stain with PSA (Nadji et al. 1981). Later, PSA was established as a blood test for 
monitoring the response of treatment for PCa (Stamey et al. 1987).  Soon thereafter, PSA 
was also introduced as a screening tool for early detection of PCa (Catalona et al.1991). 
Using a cutoff of 4mg/ml, it was shown that this test was able to detect asymptomatic 
PCA in 22 % cases. Other studies looking at the performance of PSA as a screening tool 
have shown variable results and depend on the PSA cutoff used for screening. For 
example, increasing the cutoff of PSA to higher levels improves the predictive value. 
However, if a higher cutoff is used then the number of cancers detected at early stage 
decrease and more cancers are diagnosed at an advanced stage. The lack of specificity at 
lower cutoffs subject many patients with elevated PSA, often secondary to noncancerous 
causes, to a prostate biopsy. This underscores the fact that PSA is able to identify patients 
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with prostate disease and is not specific for PCa. The area under the curve (AUC) of the 
receiver operating characteristic (ROC) curve is between 0.56 and 0.70 for the ability of 
PSA to identify patients with cancer, where a score of 1.0 is perfect discrimination and 
0.5 is a coin toss (Brawer et al. 1999). Common non-cancerous causes of elevated PSA 
levels are prostatic infection, trauma, and BPH. Studies have also shown that using the 
classic cutoff of 4mg/ml will result in missing significant number of prostate cancer cases 
(Schroder et al. 2008). If the cutoff of < 4mg/ml is considered as a negative test, a large 
study found 15.2% men in this group were actually later diagnosed to have prostate 
cancer, and according to AUA risk classification, 14.9% of these patients exhibited high 
risk disease (Thompson et al. 2004).  
To improve the predictive value of the PSA test, a number of dynamics of PSA have been 
tested. PSA density (PSAD) is one such tool. The calculations for PSAD are based on the 
concept that the normal prostate gland produces PSA but at lower concentrations. Each 
gram of normal prostate gland contributes to the total PSA but if there is a focus of 
cancer in the gland it produces significantly higher PSA. The total weight of the prostate 
is calculated by transrectal ultrasound and a predicted PSA is calculated by multiplying it 
by 0.12. Any value above the predicted value is suggestive of PCa.  In one study, no 
cases of BPH were found in men with PSAD of > 0.1 mg per each gram of prostate 
(Benson et al. 1992). However, 2 out of 41 patients with prostate cancer had a PSAD of 
0.05mg/gm or less. PSAD is a great tool to rule out BPH in men with high PSAD but 
fails to reliably rule out PCa, when PSAD is low. Recently, the role of PSAD is also 
being highlighted in the follow up of patients with low risk PCa managed with active 
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surveillance. A higher PSAD is found to be positively associated with the risk of 
progression and need for active treatment (Welty et al. 2014). 
 Age related PSA is another method to improve diagnostic efficiency. These age-specific 
reference ranges are designed to enhance the predictive value of PSA as a more 
discriminating tumor marker for detecting clinically significant cancers in older men 
(increasing specificity) and to find more potentially curable cancers in younger men 
(increasing sensitivity) (Oesterling et al. 1993). 
PSA in circulation exists in both free form and complex form, bound with alpha 1-
antichymotrypsin (ACT). Complex PSA is raised in PCa (Leinonen et al. 1993). A free to 
total PSA ratio of < 15 to 20% is generally considered to increase the risk of cancer 
(Oesterling et al. 1995). However, there is no exact watershed level. PSA velocity, the 
rate at which the PSA rises, is also used to improve the predictive value, where if the 
PSA increases by >0.75mg/ml per year it is considered to be an indication for prostate 
biopsy (Carter et al. 1993). 
Extensive research in finding ways to promote the utility of PSA as a screening tool has 
failed to develop a perfect model capable of confidently selecting men suitable for 
aggressive and life-saving treatment.  
1.4 Trans-rectal ultrasound (TRUS) guided Biopsy 
This is the main modality of obtaining prostate tissue for histological diagnosis. 
Transrectal ultrasound is used as a guide to obtain systematic samples from the prostate.  
A probe is introduced into the rectum and a needle biopsy gun is used to obtain core 
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biopsies. Specific templates are used to systematically sample the prostate gland. 
Additional samples may be obtained from sonographic or clinically suspicious areas.  
The chances of finding a focus of prostate cancer on TRUS biopsy increases with the 
number of cores taken but this may also increase the risk for complications which include 
hematuria, rectal bleeding and urinary tract infection. In North America, more than 1 
million prostate biopsy procedures are performed each year, with approximately 25% 
being positive for cancer and approximately 75% negative for cancer (Thompson et al. 
2004). The risk of complications after a prostate biopsy is not trivial, as hematuria occurs 
in 66% patients and rectal bleeding in 9% patients. Urinary tract infections occur in 0.5 to 
3% patients and in rare cases these can lead to mortality.  SEER- Medicare data reveals 
that the 30-day hospitalization rate after TRUS biopsy was 6.9%, which was significantly 
greater than the 2.7% risk of hospitalization in the control population (Loeb et al. 2011). 
Even after adjusting for age, ethnicity and comorbidities, prostate biopsy is associated 
with a 2.65-fold (95% CI 2.47-2.84) increased risk of hospitalization within 30 days, p 
<0.0001 (Loeb et al. 2011). Interestingly, the risk of infectious complications requiring 
hospitalization after biopsy was significantly greater in more recent years, probably a 
reflection of a trend to acquire more biopsy cores. Increasing the number of cores of the 
biopsy increases the sensitivity but also increases the risk of complications. It is now 
recommended to have at least 10 cores for prostates <50 gms and up to 18 cores for 
larger glands (Chun et al. 2010). But even increasing the number of cores to >20, does do 
not eliminate the possibility of missing a focus of carcinoma and this may often require a 
repeat biopsy. If we develop a better marker of the diagnosis of PCa, we may be able to 
prevent a large majority of men undergoing a prostate biopsy. This test is critically 
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needed for screening PCa. In theory, every additional 5% increase in accuracy rates for 
such a prostate screening test would eliminate approximately 165,000 unnecessary 
biopsies and 6,930 hospitalizations each year in North America. This would potentially 
result in significant health care savings and improve the quality of life of our patients. 
To meet the challenge of a screening test superior to PSA, we propose a prostate 
microparticle-based “fluid biopsy” which continually samples the prostate and its primary 
tumor. The microparticles may contain biological information from the parent cells and 
may help to gain insight regarding the biology of these tissues without the need of 
obtaining a tissue sample. 
1.5 Microparticles 
Microparticles (MP) are defined as plasma membrane derived structures of a diameter of 
less than 1000nm. They are released from the cell upon activation, death, apoptosis or 
malignant transformation (Rak, 2013).  The release of microvesicles was first described 
in 1967 by Wolf while studying the particulate dust formed by active platelets (Wolf, 
1967). MP are released directly from the cell membranes whereas, exosomes are 
enveloped by a inverted cell membrane that was first internalized and then released. Cell 
cultures from various normal and neoplastic cell lines have shown that exfoliated vesicles 
are present in the cell culture medium (Trams et al. 1981). These microparticles were 
found to contain significantly higher amounts of sphingomyelin (SM) and total 
polyunsaturated fatty acids. This study concluded that the shed MP constitute a select 
portion of the plasma membrane. Examination by electron microscopy showed the 
vesicles had an average diameter of 500 to 1000 nm. These particles were previously 
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labeled as “cell dust” or “cell garbage”, but advancements in imaging technology has 
enabled us to understand them better and this has opened up new avenues of research 
(Leong et al. 2011).  
Living cells, through outward blebbing of the plasma membrane, generate MP from the 
region of membrane lipid rafts. They exhibit high levels of exposed phosphatidylserine 
(PS), integrins and metalloproteinases (Rak, 2013).  
The process of the generation of a MP starts with vesiculation, initiated by focal and 
short-lived alterations in the plasma membrane phospholipids brought about by 
enzymatic changes. These changes produce a focal asymmetry, which is seen as a 
tentacle or a bleb. Some of these tentacles are shed off and enter the circulation. This is 
an energy-dependent and active mechanism, which maintains an architectural uniformity 
of the cell. This process guarantees that phosphatidylcholine and SM remain on the outer 
surface of the plasma membrane and phosphatidylserine, and phosphatidylethanolamine 
are present on the inner side. This action is brought about by lipid-translocating enzymes 
(flippases). Calcium is an integral part of this process because cytosolic calcium initiates 
significant changes in the state of the enzymes responsible for generation of MP. 
Aminophospholipid translocase, scramblase, gelsolin, lipid, floppase, and calpain are the 
main enzymes identified to play an important role in this process (Rak, 2013). This 
ultimately results in externalization of PS and changes in the membrane geometry. These 
cytoskeletal interactions are critical for the formation of the tentacles or blebs, which 
ultimately leads to the formation and release of a MP. 
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MP can be visualized using electron microscopy for morphological characterization. 
Gold-labeled immune electron microscopy was first used to assess the urinary MP 
(Mitchell et al. 2009).  With the microparticles fluorescently labeled, MP can also be 
visualized indirectly using confocal microscopy (CM). However, MP are too small for 
direct visualization with standard CM. The lipophilic fluorescent dyes conjugated with 
antibodies against the antigens expressed on the plasma membranes of the MP can help 
detect them with relative ease. Dr. Leong, at our laboratory has validated the presence of 
MP analyzed using flow cytometry (Leong et al. 2011) and by atomic force microscopy 
(Leong et al. 2010).  Figure 3 shows atomic force microscopy images of prostate cancer 
microparticles. 
The exact role of these MP is still elusive but there is great enthusiasm in the scientific 
community to explore the role of these structures in the vesicular transportation system 
both for intracellular and extracellular communication. In 2013, James Rothman, Randy 
Schekman and Thomas Sudhof were presented with the Nobel Prize for their work on the 
role of micro vesicles for intracellular transportation. Similarly, plasma membrane 
derived microparticles may also have a role in the extracellular 
transportation/communication (Camussi et al. 2010).   
As with other newly discovered structures, these < 1 µm structures have been described 
in the literature using a variety of terminologies; microparticles, microvesicles, 
exosomes, oncosomes, secretory vesicles, ectosomes are a few examples. The 
terminologies have mostly originated from either the disciplines in where they have been 
studied or more recently based on the size. The most widely studied structures in this 
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category are the Exosomes that have a size up to 500nm (Pan, 1983) and have an 
established role in cellular communication. 
 
. 
 
 
Figure 3 Atomic force microscopy images depicting the structure of individual prostate 
specific membrane antigen (PSMA) positive microparticles 
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However, the mechanism of release of exosomes is very different as they are first 
internalized and then reprocessed for release (Duijvesz et al. 2011). Ectosomes are 
plasma cell derived structures but are mainly released as a result of apoptosis (Diamant  et 
al. 2004).  To avoid use of confusing terminologies we will refer to microvesicles, 
exosomes, oncosomes, secretory vesicles and ectosomes as ‘Microparticle (MP)’ in our 
discussion. There is growing consensus that MP is the best-suited terminology to describe 
these biologically diverse structures. 
The exact physiological importance of these structures in the development of cancer is 
not known. MP are enriched with specific antigens (Clayton et al. 2009). Elegant 
experiments in immunology have shown that MP affects the immune system by 
expressing and processing antigens (Raposo et al. 1996). As MP retains the surface 
characteristics of parent cells they may have a role in antigen presentation and 
immunomodulation. They may play a role in either promotion or prevention of 
metastasis. Assuming this is the mechanism of their release into the circulation, this 
feature may be exploited to develop diagnostic markers, which can function as a “fluid 
biopsy” of the entire gland.  
Currently, prostate cancer microparticles is an emerging topic in oncology research, but 
many researchers lack the instrumentation needed to translate this work into clinical 
applications. Enumeration of MP in a sample remains a challenge. The number of MP is 
generally estimated by measuring the amount of protein (Nilsson et al. 2009). 
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Fluorescence-activated cell sorting (FACS) technology i.e. flow cytometer is capable of 
enumerating MP but identification of organ specific MP, which are relatively tiny 
compared to a cell, is difficult using a regular flow cytometry system due to the 
limitations of laser detectors. Other visualization techniques such as electron microscopy 
(EM) and confocal microscopy (CM) described previously are good for morphological 
characterization but cannot perform quantitative assays in a high throughput manner. A 
combination of enzyme-linked immunosorbent assay (ELISA) for exosome quantification 
has been used (Logozzi et al. 2009). In this experiment they used two different 
transmembrane proteins that are present on all exosomes. They postulated that by using 
one general transmembrane protein or so called ‘capture protein’, it is possible to identify 
exosomes and by using ‘tissue- or cancer-specific’ transmembrane protein, the number of 
exosomes derived from a specific tissue can be measured. 
We used a similar hypothesis and selected prostate specific membrane antigen (PSMA) 
as the capture marker for identification of prostate specific MP. For cancer specific 
marker we selected ghrelin peptide and gastrin releasing peptide receptor (GRPR). We 
postulated that a combination of more than two markers would improve our ability to 
select the population of prostate cancer MPs. We proposed to do this using flow 
cytometry. Improvement in this technology with development of Agogee, A-50 nanoscale 
flow cytometer (® Apogee Flow systems, Hertfordshire, UK) has provided us the 
capacity to enumerate particles of less than one micron. 
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1.6 Instruments 
We used a specialized instrument that analyzes cell fragments in a high-throughput, 
multi-parametric manner. This nanoscale flow cytometer is manufactured by Apogee 
Flow systems Incorporation, Hertfordshire, UK. The “Apogee A-50 micro nanoscale 
flow cytometer” shown in Figure 4, is specifically designed to analyze and enumerate 
cancer microparticles. This machine has three lasers installed; the Laser wavelengths are 
375nm, 405nm, 488nm and 635nm. The multiple light scattering and fluorescence 
detectors help increase the detection limit to <100nm and increase the resolution to 
<10nm. Figure 5 shows the basic design of the machine, the florescence channels and the 
laser with exposure to the column of cells. This machine is equipped with Peripheral 
Component Interconnect Express (PCIe), high-speed computer software used for data 
acquisition. It employs the latest Altera™ technology for data acquisition at speed of up 
to 100k events per second.  Conventional flow cytometers rely on fluorescent probes to 
measure biological particles smaller than 500nm, this may produce dim signals and data 
may be inconsistent. The A50-Micro's light scatter performance allows small particles to 
be better discriminated.  
Since our previous study demonstrated that prostate cancer MP are abundant in plasmas, 
we performed multi-parametric analyses with prostate-specific and cancer-specific 
biomarkers (Siddiqui et al. 2014). We used a combination of antibodies that bind 
prostate-specific and cancer-specific markers present in just 20 µl of patient plasma. Our 
initial experience of enumeration of MPs in the plasma samples from a PCa patient 
before and after radical prostatectomy and our previous pilot study encouraged us to use 
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this machine to develop a test to distinguish patients with benign prostatic hyperplasia 
(BPH) from patients with prostate cancer.  
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Figure 4. Apogee A50 Nanoscale Flow cytometer 
 28 
 
 
 
 
 
Figure 5. Fundamental framework of a flow cytometer with florescence channels and the 
laser detectors 
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1.7 Prostate Cancer Surface Receptors 
Cells originating from a specific organ typically manifest some receptors exclusive to that 
organ. This usually helps in classifying the cell to the organ of origin. Histological 
interpretation of specimens from metastatic sites with unknown primary lesion have long 
relied on using monoclonal antibodies against cell specific receptors to identifying the 
origin of these metastatic lesions. Recently, they have attracted attention and are 
increasingly used to develop therapeutic and diagnostic agents for treatment of cancers 
(Deckert et al. 2009). These antibodies are conjugated with florescence dyes and used in 
imaging modalities. For example, the Prostascint scan uses PSMA to look for metastatic 
lesions from PCa (Rosenthal et al. 2001). Ghrelin has been used as a PET imaging agent 
to identify foci of carcinomas in the prostate gland (Fowkes, 2014). We hypothesize that 
these antibodies may be used to identify microparticles, as it is postulated that a MP 
retains the surface receptors from the parent cells. With the use of appropriate antibodies 
it may be possible to establish the lineage of the MP. Monoclonal antibodies (mAbs) are 
highly specific and adaptable for targeting cells. We used two antibodies against two 
surface receptors expressed on PCa cells namely, prostate specific membrane antigen 
(PMSA) and gastrin releasing peptide receptor (GRPR). We also used a peptide-ligand 
called Ghrelin. The antibodies and the peptide-ligand were conjugated with fluorescent 
agents and used to enumerate the MP using flow cytometry.   
1.7.1 Prostate specific Membrane Antigen (PSMA) 
PSMA is a type II transmembrane protein. It has a helical structure with an N-terminal 
cytoplasmic tail and was first cloned in 1993 (Israeli et al. 1993). This transmembrane 
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protein consists of a small intracellular domain of 19 amino acids, a transmembrane 
domain of 24 amino acids, and a large extracellular domain of 707 amino acids. The 
extracellular portion consists of a binding motif, including two zinc ions. The presence of 
PSMA is not actually unique to the prostate (Sacha et al. 2007). Its structure is almost 
identical to folate hydrolase and it is confirmed to be present in four sites in the body: 
prostate (secretory acinar epithelium), kidney (proximal tubules), nervous system glia 
(astrocytes and schwann cells), and the small bowel (Mhawech et al 2007). The 
physiological significance of PSMA in not completely understood in the prostate gland 
but it may be linked to the presence of folates in the seminal fluid. As intracellular folate 
is more abundant in rapidly dividing cells it is postulated that it may be more expressed in 
the higher grade prostate cancers.  
PSMA was first identified in the prostate using IgG1 monoclonal antibody called 7E11-
C5.3. This antibody was developed using the prostate cancer cell line known as LNCaP 
and was also used in development of Prostascint scan (Horoszewicz et al. 1987). This 
scan was approved by U.S. Food and Drug Administration (FDA) to be used as 111In-
labeled form (ProstaScint, Cytogen, Philadelphia, PA) but gained limited success 
(Rosenthal et al 2001). The main flaw in this antibody was that it had affinity for the 
intracellular portion and hence was not useful to identify living cells. Wolf et al 
developed three other mAbs (3/A12, 3/E7, 3/F11), which show a strong and specific 
extracellular binding to PSMA (Wolf et al. 2010). Wolf also demonstrated that 3/E7 was 
compatible with flow cytometric analysis and showed high affinity to human prostate 
tissue. This antibody could be obtained with >95% purity from the hybridoma. 
Progressively increasing expression of PSMA has been demonstrated in BPH, high grade 
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prostatic intraepithelial neoplasia (PIN) and prostate cancer (Bostwick et al. 1998). 
Similar association of PSMA expression in high grade prostate cancer has been shown by 
other investigators (Wright et al. 1995). This data support potential clinical use of PSMA 
in the diagnosis of PCa.  
1.7.2 Ghrelin 
Ghrelin peptide is a ligand for Growth Hormone Secretagogue Receptor (GHSR). Growth 
hormone (GH) is mainly released from the pituitary gland in response to growth hormone 
releasing hormone (GHRH) but there is also another pathway related to G-protein 
coupled receptor called growth hormone secretagogue receptor (GHSR). This receptor 
was first cloned in 1996 and unlocked the door for future research in this direction 
(Howard et al. 1996). The ligand for GHSR was purified in 1999 and named as Ghrelin, 
‘ghre’ is the Proto-Indo-European root of the word 'grow' (Kojima et al. 1999).  Ghrelin 
is composed of 28 amino acids, in which the 3-serine residues are n-octanoylated. The 
acylated peptide specifically releases GH both in vivo and in vitro, and O-n-octanoylation 
at 3-serine is essential for the activity. GHSR is also differentially expressed in human 
breast cancer cell lines (Casoni et al. 2001).  Other studies have also documented that 
differential expression of GHSR in PCa and showed that Ghrelin has a role in growth of 
prostate cancer cell lines (Jeffery at al. 2002).  He observed a 33% increased growth in 
the PC-3 cell lines when stimulated by ghrelin. Our collaborator, Dr. Luyt and colleagues 
at Western University modified the structure of ghrelin and created a novel fluorescent 
ghrelin analogue. They demonstrated the binding and uptake of this fluorescent ghrelin 
analogue in human PCa cells and showed the ability of Ghrelin to specifically bind PCa 
over normal adjacent tissue (Rosita et al. 2009). In our previous work using ex vivo 
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tissue, we were able to demonstrate that this novel fluorescein-ghrelin probe was able to 
distinguish between benign and cancerous cell lines and therefore has potential to be 
explored as a marker for diagnosis of PCa (Lu et al. 2012). In our pilot study, we have 
shown the usefulness of Ghrelin as our cancer-specific biomarker to define the population 
of prostate cancer microparticles in plasma. In the pilot study, we enumerated PSMA+ 
and GHSR+ microparticles in plasmas from three patient cohorts and found higher counts 
of PSMA+ GHSR+ dual positive MP in the metastatic and localized prostate cancer 
patient cohorts compared to the low counts observed in healthy volunteers. Based on this 
experience we elected to investigate Ghrelin as a biomarker in this study. 
1.7.3 Gastrin Releasing Peptide Receptor (GRPR) 
GRPR is a G-protein coupled receptor belonging to the family of Bombesin receptors. 
Bombesin is a 14-amino acid peptide, originally isolated from the skin of the European 
fire-bellied toad (Bombina bombina) (Nakajima et al. 1980). Erspamer, further 
characterized and isolated them (Erspamer, 1988).   Gastrin Releasing Peptide (GRP) 
mediates its action through the membrane-bound GRPR. It activates several signaling 
pathways including those involved in cell cycle regulation (Jensen et al. 2008). GRPR 
expression has been identified on PC-3 prostate cancer cells  (Bologna et al. 1989). Their 
differential expression was also documented in the breast cancer cell line (Giacchetti et 
al. 1990). These studies lead the way for further exploration of GRPR in the process of 
carcinogenesis. It has also been shown that antagonists of GRP can inhibit the growth of 
prostate cancer cells. (Milovanovic et al. 1992). GRPR also has been shown to be over 
expressed in PCa (Ananias et al. 2009). In this study they found GRPR staining in lymph 
node metastases in 85.7% of cases and PSMA staining in 100%. GRPR expression was 
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found to be present in 52% of the bone metastases. Another study also looked at GRPR 
expression in 299 primary prostate carcinomas and found 77% cases positive for GRPR 
(Beer et al. 2012). They also found inverse relation with the grade and volume of disease. 
 In this study our hypothesis is that PCa cell release MP in the circulation. These MP 
express surface receptors which are inherited from their cell of origin. Our literature 
review suggests that PSMA, GRPR and GHSR are abundantly expressed on PCa cells.. 
Monoclonal antibodies and ligands specific for these receptors can be used as biomarkers 
for PCa. A combination of these biomarkers including PSMA mAb and Ghrelin-peptide 
and/or GRPR mAb can help us isolate PCMP in plasma samples to discriminate patients 
with PCa from patients with BPH. 
 34 
 
 
1.8 Bibliography 
Ananias HJ, van den Heuvel MC, Helfrich W & de Jong IJ. (2009). Expression of the 
gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific 
membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69, 
1101–1108. 
Andreu Z & Yáñez-Mó M. (2014). Tetraspanins in extracellular vesicle formation and 
function. Front Immunol 5, 442.  
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, 
Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, 
Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, 
Prorok PC, Gohagan JK & Berg CD; PLCO Project Team. (2009). Mortality results from 
a randomized prostate-cancer screening trial. N Engl J Med 360, 1310-9. 
Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Müntener M & 
Kristiansen G. (2012). Profiling gastrin-releasing peptide receptor in prostate tissues: 
clinical implications and molecular correlates. Prostate. 72, 318-25. 
Benson MC1, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. 
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy 
and prostate cancer. J Urol. 1992 Mar;147(3 Pt 2):815-6. 
 35 
 
Bologna M, Festuccia C, Muzi P, Biordi L & Ciomei M. (1989). Bombesin stimulates 
growth of human prostatic cancer cells in vitro. Cancer 63, 1714-1720. 
Bostwick DG, Pacelli A, Blute M, Roche P & Murphy GP. (1998). Prostate specific 
membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma:a 
study of 184 cases. Cancer 82, 2256–61. 
Brawer MK. (1999) Prostate-specific antigen: current status. CA Cancer J Clin 49, 264-
81. 
Camussi G, Deregibus MC, Bruno S, Cantaluppi V & Biancone L. (2010). 
Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 8, 
838–48. 
Carter HB & Pearson JD. (1993). PSA velocity for the diagnosis of early prostate cancer. 
A new concept. Urol Clin North Am 20, 665-670. 
Carter HB, Piantadosi S & Isaacs JT. (1990). Clinical evidence for and implications of 
the multistep development of prostate cancer. J Urol 143, 742–746.  
Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, Deghenghi R, 
Reissmann T, Ghigo E & Muccioli GJ (2001). Identification, characterization, and 
biological activity of specific receptors for natural (ghrelin) and synthetic growth 
hormone secretagogues and analogs in human breast carcinomas and cell lines. Clin 
Endocrinol Metab 86, 1738-45. 
 36 
 
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA & 
Andriole GL. (1991). Measurement of prostate-specific antigen in serum as a screening 
test for prostate cancer. N Engl J Med 324, 1156-61. 
Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, Shariat SF, 
Schröder FH & Scattoni V. (2010). Optimizing performance and interpretation of 
prostate biopsy: a critical analysis of the literature. Eur Urol 58, 851-64. 
Clayton A & Mason MD. (2009). Exosomes in tumour immunity. Curr Oncol 16,46–49. 
Crawford ED. (2003).  Epidemiology of prostate cancer. Urology 22, 3-12. 
Deckert PM. (2009) Current constructs and targets in clinical development for antibody-
based cancer therapy. Curr Drug Targets 10, 158–175. 
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins 
AS & Jemal A. (2014). Cancer treatment and survivorship statistics, 2014. CA Cancer J 
Clin. 64, 252-71. 
Diamant M, Tushuizen ME, Sturk A & Nieuwland R. (2004). Cellular microparticles: 
new players in the field of vascular disease?. Eur J Clin Invest 34, 392–401. 
Diederick Duijvesz , Theo Luider , Chris H. Bangma & Guido Jenster. (2011) Exosomes 
as Biomarker Treasure Chests for Prostate Cancer  Eur Urol  5 9, 8 2 3 – 8 3 1. 
Epstein JI, Allsbrook WC Jr, Amin MB & Egevad LL. (2005). The 2005 International 
Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of 
Prostatic Carcinoma, Am J Surg Pathol 29, 1228-42. 
 37 
 
Erspamer V. (1988). Discovery, isolation, and characterization of bombesin-like peptides. 
Ann N Y Acad Sci 547, 3-9. 
Fowkes & Milan M. "Peptidomimetic GHS-R1a Agonists as PET Imaging Agents for 
Prostate Cancer" (2014). University of Western Ontario - Electronic Thesis and 
Dissertation Repository. Paper 1972. 
Giacchetti S, Gauville C, De Cremoux P, Bertin L, Berthon P, Abita JP, Cuttitta F & 
Calvo F. (1990). Characterization, in some human breast cancer cell lines, of gastrin-
releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J 
Cancer; 46: 293-298. 
Gleason DF & Mellinger GT. (1974). Prediction of prognosis for prostatic 
adenocarcinoma by combined histological grading and clinical staging. J Urol 111, 58-
64. 
Horoszewicz JS, Kawinski E & Murphy GP.  (1987). Monoclonal antibodies to a new 
antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. 
AnticancerRes 7, 927–35. 
Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin 
M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee 
KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, 
Sirinathsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, 
DeMartino JA, Gupta SK, Schaeffer JM, Smith RG & Van der Ploeg LH. (1996). A 
 38 
 
receptor in pituitary and hypothalamus that functions in growth hormone release. 
Science. 273, 974-977. 
http://www.cancer.ca/en/cancer-information/cancer-type/prostate/statistics/region. 
http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm. 
Israeli RS, Powell CT, Fair WR & Heston WD. (1993) Molecular cloning of a 
complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 
53,227–30. 
Jeffery PL, Herington AC & Chopin LK. (2002). Expression and action of the growth 
hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J 
Endocrinol 172, 7–11. 
Jemal A, Siegel R, Xu J & Ward E. (2010). CA Cancer J Clin 60, 277-300. 
Jensen RT, Battey JF, Spindel ER & Benya RV. (2008). International Union of 
Pharmacology. LXVIII. Mammalian bombesin receptors: Nomenclature, distribution, 
pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 60, 
1–42. 
Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian 
LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, 
Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, & Baker 
LH. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E 
Cancer Prevention Trial (SELECT) JAMA. 306, 1549-56. 
 39 
 
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H & Kangawa K. (1999). Ghrelin is 
a growth-hormone-releasing acylated peptide from stomach. Nature. 402, 656-660. 
Kotwal AA, Schumm P, Mohile SG & Dale W. (2012). The influence of stress, 
depression, and anxiety on PSA screening rates in a nationally representative sample. 
Med Care. 50, 1037-44. 
Leong HS, Podor TJ, Manocha B & Lewis JD. (2011). Validation of flow cytometric 
detection of platelet microparticles and liposomes by atomic force microscopy. J Thromb 
Haemost 9, 2466-76. 
Leong HS, Steinmetz NF, Ablack A, Destito G, Zijlstra A, Stuhlmann H, Manchester M 
& Lewis JD (2010). Intravital imaging of embryonic and tumor neovasculature using 
viral nanoparticles. Nat Protoc 5,1406-1417. 
Leinonen J1, Lövgren T, Vornanen T & Stenman UH. (1993). Double-label time-
resolved immunofluorometric assay of prostate-specific antigen and of its complex with 
alpha 1-antichymotrypsin. Clin Chem 39, 2098-103. 
Loeb S, Carter HB, Berndt SI, Ricker W & Schaeffer EM. (2011). Complications after 
prostate biopsy: data from SEER-Medicare. J Urol 186, 1830-1834. 
Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, 
Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, 
Huber V, Maio M, Rivoltini L & Fais S. (2009). High levels of exosomes expressing 
CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 4, 5219. 
 40 
 
Lu C, McFarland MS, Nesbitt RL, Williams AK, Chan S, Gomez-Lemus J, Autran-
Gomez AM, Al-Zahrani A, Chin JL, Izawa JI, Luyt LG, Lewis JD. Ghrelin receptor as a 
novel imaging target for prostatic neoplasms. Prostate. 2012 Jun 1;72(8):825-33. 
Mandair D, Rossi RE, Pericleous M, Whyand T & Caplin ME. (2014).  Prostate cancer 
and the influence of dietary factors and supplements: a systematic review. Nutr Metab 6, 
30. 
Martinez CH, Williams AK, Chin JL, Stitt L& Izawa JI. (2013). Perineural invasion and 
TRUS findings are complementary in predicting prostate cancer biology. Can J Urol 20, 
6696-701. 
McNeal JE. (1980). Anatomy of the prostate: an historical survey of divergent views. 
Prostate 1, 3-13. 
Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, & 
Penetrante R.. (2007). Prostate- specific membrane antigen (PSMA) protein expression in 
normal and neoplastic tissues and its sensitivity and specificity in prostate 
adenocarcinoma:  an immunohistochemical study using mutiple tumour tissue microarray 
technique. Histopathology 50, 472–83. 
Milovanovic Sr, Radulovic S, Groot K & Schally AV. (1992). Inhibition of growth of 
PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-
3095 or combination of agonist [D-Trp6]- luteinizing hormone-releasing hormone and 
somatostatin analog RC-160. Prostate  20, 269-280 
 41 
 
Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z & Clayton A. (2009). Can 
urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 7, 
4. 
Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC & Morales AR. (1981). 
Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 
48, 1229-32. 
Nakajima T, Yasuhara T, Erspamer V, Erspamer GF, Negri L & Endean R. (1980). 
Physalaemin- and bombesin-like peptides in the skin of the Australian leptodactylid frog 
Uperoleia rugosa. Chem Pharm Bull 28, 689-95. 
Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO & 
Widmark A. (2009). Prostate cancer-derived urine exosomes: a novel approach to 
biomarkers for prostate cancer. Br J Cancer 100, 1603–7. 
Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA & Lieber MM. 
(1993).  Serum prostate-specific antigen in a community-based population of healthy 
men. Establishment of age-specific reference ranges. JAMA. 270, 860-4. 
Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, 
Stenman UH, Dowell B, Lövgren T &  Lilja H. (1995).  Free, complexed and total serum 
prostate specific antigen: the establishment of appropriate reference ranges for their 
concentrations and ratios. J Urol. 154, 1090-1095. 
Pan BT & Johnstone RM. (1983). Fate of the transferrin receptor during maturation of 
sheep reticulocytes in vitro: selective externalization of the receptor. Cell 33, 967–78. 
 42 
 
Rak J. (2013). Extracellular vesicles - biomarkers and effectors of the cellular 
interactome in cancer. Front Pharmacol 4, 21. 
Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, & 
Geuze HJ. (1996). B lymphocytes secrete antigen-presenting vesicles. J Exp Med 
183,1161–72. 
Rosenthal SA, Haseman MK & Polascik TJ. (2001). Utility of capromab pendetide 
(ProstaScint) imaging in the management of prostate cancer. Tech Urol 7, 27–37. 
Rosita D, Dewit MA & Luyt LG.  (2009). Fluorine and rhenium substituted ghrelin 
analogues as potential imaging probes for the growth hormone secretagogue receptor. J 
Med Chem 52, 2196-2203. 
Sacha P, Zamecnik J, Barinka C, Hlouchová K, Vícha A, Mlcochová P, Hilgert I, 
Eckschlager T, Konvalinka J. (2007). Expression of glutamate carboxypeptidase II in 
human brain.Neuroscience 144, 1361–72. 
Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, & 
Roobol MJ. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur 
Urol 53, 468-77. 
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, 
Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma 
CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de 
Koning HJ & Auvinen A; ERSPC Investigators. (2009). Screening and prostate-cancer 
mortality in a randomized European study. N Engl J Med 360, 1320-8. 
 43 
 
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski 
M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, 
Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, 
Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, & Auvinen A. 
(2014). Screening and prostate cancer mortality: results of the European Randomised 
Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, Aug 6.  
Scosyrev E, Wu G, Mohile S & Messing EM. (2012). Prostate-specific antigen screening 
for prostate cancer and the risk of overt metastatic disease at presentation : Analysis of 
trends over time. Cancer 118, 5768-76. 
Siddiqui KM, Biggs C, Billia M, Mazzola CR, Izawa J, PowerN, Chin J & Leong HS.. 
(2014). Enumeration of Prostate Cancer Microparticles as a Tool to Identify Prostate 
Cancer. CUAJ 8, 5-6  
Siegel R, Ma J, Zou Z, Jemal A. (2014). CA Cancer J Clin 64, 9-29. 
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS & Redwine. (1987).  Prostate-
specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 
317, 909-16. 
Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE & Mack TM. (1991). 
Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles 
County. Br J Cancer 63, 963-6. 
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian 
LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ & Coltman CA Jr. (2004). 
 44 
 
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 
ng per milliliter. N Engl J Med 350, 2239-46.  
Trams EG, Lauter CJ, Salem N Jr & Heine U. (1981). Exfoliation of membrane ecto-
enzymes in the form of micro-vesicles. Biochim Biophys Acta 645, 63-70. 
Wang MC, Valenzuela LA, Murphy GP & Chu TM. (1979). Purification of a human 
prostate specific antigen.Invest Urol 17, 159-63. 
Wein AJ, Kavoussi LR,  Novick AC, Partin AW  & Peters CA, eds. Campbell-Walsh 
Urology, 10th Edition. Philadelphia: Saunders, 2010. 
Welch HG, Fisher ES, Gottlieb DJ & Barry MJ. (2007). Detection of prostate cancer via 
biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst. 99, 
1395.  
Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng 
MV, Simko JP, Cooperberg MR & Carroll PR. (2014). Extended Follow-Up and Risk 
Factors for Disease Reclassification from a Large Active Surveillance Cohort for 
Localized Prostate Cancer. J Urol. Sep 24.  
Wolf P. (1967). The nature and significance of platelet products in human plasma. Br J 
Haematol 13, 269-288. 
Wolf P, Freudenberg N, Buhler P, Alt K, Schultze-Seemann W, Wetterauer U & 
Elsa¨sser-Beile U. (2010). Three Conformational Antibodies Specific for Different 
 45 
 
PSMA Epitopes Are Promising Diagnostic and Therapeutic Tools for  Prostate Cancer. 
The Prostate 70, 562-569. 
Wright GLJr, Haley C, Beckett ML & Schellhammer PF. (1995).Expression of prostate-
specific membrane antigen in normal, benign ,and malignant prostate tissues. UrolOncol 
1,18–28. 
 46 
 
Chapter 2  
2 Pilot Study: Enumeration of Prostate Cancer Microparticles 
as a Tool to Identify Prostate Cancer   
2.1 Introduction 
The search for development of an ideal tumor marker for prostate cancer has been on 
going for the better part of the last half century. There is a long list of emerging 
biomarkers for diagnosis and prognosis of prostate cancer (PCa) (Velonas et al. 2013). 
Only a few biomarkers have been able to survive the stringent tests of large clinical trials 
and prostate specific antigen (PSA) continues to be the most widely used marker for PCa. 
The current guidelines by the American Urology Association (AUA) only permit PSA 
testing for individuals between age 55 and 64 who understand the risks associated with 
PSA based screening (www.auanet.org).  The AUC analysis for ability of PSA to 
confidently diagnose PCa is in the range of 0.56- 0.70 (Brawer et al. 1999). A recent 
report of the ESRPC trial report that 781 men are needed to be screened with PSA to 
prevent one PCa related death (Shroder et al. 2014). To meet the challenge of developing 
a screening test superior to PSA, we proposed a microparticle (MP) based test that 
enumerated prostate cancer MPs in minute volumes of patient blood in a high-throughput 
and multi-parametric manner. This pilot study is aimed to validate the clinical utility of 
this test to successfully distinguish patients with PCa from those who did not have 
cancer. 
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2.2 Material and Methods 
We used A-50 Apogee, nanoscale flow cytometer which is specifically designed to 
analyze and enumerate cancer microparticles, to study prostate cancer microparticles 
present in four cohorts of patients: 
a. Healthy volunteers (HV) (n=24); Included young men and women aged <35 with 
no known cancers. 
b. Benign Prostatic Hypertrophy (BPH) (n=10); Included men who had a normal 
digital rectal examination and had a transurethral resection of prostate with a 
pathologic diagnosis of BPH. 
c. Localized Prostate Cancer (n=112): Samples obtained from Ontario Institute of 
Cancer (OICR) from patients undergoing radical prostatectomy for localized 
prostate cancer. 
d. Metastatic Prostate Cancer (n=23): Included samples from patients with 
metastatic castrate resistant prostate cancer. 
We used a monoclonal antibody specific to the extracellular portion of PSMA (PSMA-
RPE mAb) and ghrelin peptide, a growth hormone secretagogue receptor (GHSR) ligand 
(Ghrelin-FITC ligand) to identify and enumerate dual positive prostate cancer 
microparticles (PSMA + Ghrelin dual positive). 
For the HV and BPH group we collected 1 vacutainer from each patient (10 mL sodium-
heparin Green top tubes) of whole blood. The vacutainer was centrifuged at 2000 RCF 
for 20 min. This resulted in the blood separating into two distinct layers, a red layer 
(erythrocytes) and a yellow upper layer (platelet poor plasma-PPP). Using a plastic 
disposable pasteur pipet, the PPP was transferred into 3ml tubes and stored at -80ºC. 
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Before the experiment, we thawed PPP in the tube and transferred 20 uL to a sterile 1.5 
mL eppendorf tube. This was designated as tube A. Using a 20 uL pipetman, another 20 
uL of PPP was transferred to another sterile 1.5 mL eppendorf tube and labeled as tube B. 
2uL each of IgG-FITC antibody and IgG-RPE antibody was then added to tube A. 2uL of 
Ghrelin-FITC ligand and 2uL of PSMA-RPE antibody was also added to tube B. Both the 
tubes A and B were mixed and immediately incubate in the dark for 30 min. 600uL of 
sheath fluid (1X PBS, pH 7.4) was then added to each tube and samples were vortexed. 
Samples were then analyzed using flow cytometry. Samples were analyzed in triplicates 
and the average calculated.  
2.3 Results 
We analyzed 169 plasmas and found significantly higher counts (p<0.01, ANOVA, bon 
ferroni test) of PSMA + Ghrelin, dual positive prostate cancer microparticle (PCMP) in 
patients with prostate cancer as compared to BPH and healthy volunteers. The numbers 
of PCMP in each group are shown in Figure 6.  
However we did not find any significant correlation between the number of PCMP and 
Gleason score (one-way ANOVA test). The number of PCMP in each category of 
Gleason score are shown in Figure 7. 
We did not find any correlation between number of PCMP and Tumor Stage (one-way 
ANOVA test). Figure 8 shows the number of PCMP in each ‘T’ category. Similarly no 
statistical difference was observed between the numbers of PCMP in the localized group 
and metastatic group.  Figure 9 shows the distribution of PCMP counts in various patient 
cohorts.  The scatter plots with means and respective 95% confidence intervals (red lines) 
reveal a cutoff (green dashed line) for distinguishing BPH patients from patients with  
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Figure 6.  Comparison of Number of Prostate Cancer Microparticles (PCMP) 
Expressing PSMA+ Ghrelin, Dual Positive Events in Plasmas from Four 
Groups, Including Healthy Volunteers (HV) and Benign Prostatic Hypertrophy 
(BPH), Representing A Population with No Cancer and  Other Two Groups; 
Localized Prostate Cancer and Metastatic Prostate Cancer, Representing A 
Population with Cancer.. 
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Figure 7. Comparison of Number of Prostate Cancer Microparticles (PCMP) Expressing 
PSMA+ Ghrelin, Dual Positive Events in Plasmas from Prostate Cancer Patients with  
Gleason Score 3+3,  3+4, 4+3, 4+4 and 5+4. 
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Figure 8.  Comparison of Number of Prostate Cancer Microparticles (PCMP) Expressing 
PSMA+ Ghrelin, Dual Positive Events in Plasmas from Prostate Cancer Patients with 
Tumor Stages; T2a, T2b, T2c and T3. 
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Figure 9. Distribution of Number of Prostate Cancer Microparticles (PCMP) Expressing 
PSMA+ Ghrelin, Dual Positive Events in Plasmas from Four Groups, Including Healthy 
Volunteers (HV) and Benign Prostatic Hypertrophy (BPH), Representing A Population 
with No Cancer and  Other Two Groups; Localized Prostate Cancer and Metastatic 
Prostate Cancer, Representing A Population with Cancer..  The Green Dashed Line 
Distinguishes Patients with PCa from patients with No Cancer.   
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PCa.  With this cutoff, the blood test is 89% accurate in identifying patients with PCa 
(localized PCa cohort) with 20% of patients being mistakenly identified as having PCa.   
2.4 Discussion 
Prostate cancer (PCa) is a leading cause of cancer-related death of men in the western 
world (Siegel et al. 2014). Majority of men are diagnosed with PCa based on a raised 
prostate specific antigen (PSA). Since its introduction, PSA has generated intense debate 
as an effective screening tool for PCa (Catalona et al. 1991). The recent 
recommendations by United States Preventive Task Force (USPSTF) has concluded that 
PSA based screening produces unacceptably high rates of false positive results and 
causes more harm than benefit.  
The National Cancer Institute defines a biomarker as “a biological molecule found in the 
blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a 
condition or disease”.  An ideal biomarker for PCa should not only be able to screen with 
high sensitivity and specificity but also predict the course of disease and help select high 
risk individuals for aggressive treatment. The ideal tumor marker should be economical, 
reproducible, non-invasive, not time consuming to perform and easily accessible for 
majority of population (Velonas et al. 2013). 
Microparticles (MP) are plasma membrane derived structures of a diameter of less than 
1000nm. The introduction of MP as a diagnostic test could enable more sensitive 
detection than current methods due to their origin and specificity (Rak 2013). A recent 
review of MPs, highlighted the importance of these sub micron structures as a biomaker 
for cancer (Gyorgy B et al. 2011). MP are secreted into the circulation, urine and semen, 
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thus if reliably identified, they can be exploited as biomarker treasure chests for prostate 
cancer (Dujivesz D et al. 2011).  The main function of MP is proposed to be cell-to-cell 
communication but they are likely to play a significant role in oncogenesis (Yang et al. 
2011). Exosomes (very similar to MP) have also been shown to promote metastasis by 
avoiding detection by immune system (Yang et al. 2007). 
We developed a MP based blood test to identify patients with PCa using a combination of 
monoclonal antibody for prostate specific membrane antigen (PSMA) and ghrelin 
peptide, a ligand for growth hormone scretagogue receptor (GHSR). PSMA has been 
shown to be highly expressed on prostate cells and differential expression has been 
documented on high grade prostate cancer compared to BPH and normal prostate gland 
(Wright et al. 1995). Similarly, ghrelin has been shown to bind more strongly with PCa in 
both in vitro and ex vivo experiments (Lu et al. 2012).    
Our results showed that PSMA + Ghrelin, dual positive MP are more abundant in PCa 
patient plasmas compared to plasma samples from healthy volunteers and patients with 
BPH. Compared with other established makers like PSA and prostate cancer antigen 
(PCA) 3 score, which have a diagnostic accuracy of 56% to 72% (Crawford et al. 2012).  
This blood test is able to identify PCa with a diagnostic accuracy of 89% in only a minute 
volumes of patient blood in a high-throughput and multi-parametric manner.  
2.5 Conclusion 
Our initial results show that the MP based blood test using PSMA+ Ghrelin as biomarker 
for PCa is capable of fulfilling the requirements of an ideal tumor marker and has 
potential to be the "Next Generation Screening Tool" for Prostate Cancer.  
 55 
 
 
2.6 Limitations 
The major limitation of this study was the disproportionately higher number of patients 
with prostate cancer. The total numbers of patients with PCa were 135 (112+23) 
compared to only 10 patients with BPH. Even if we combined BPH and healthy 
volunteers, the number was only 34 (24+10). In this pilot study the sample were neither 
randomized nor was the observer blinded.  
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Chapter 3  
3 Prostate Cancer Microparticles as a Next Generation 
Screening Tool for Prostate Cancer 
 
3.1 Introduction 
Prostate cancer (PCa) is the leading cancer among adult males and is one of the few solid 
organ malignancies, which can be diagnosed and monitored using a tumor marker i.e. 
prostate specific antigen (PSA). However PSA is not a true tumor marker and is also 
produced by normal prostate gland and may be raised in a number of benign conditions. 
Large studies have shown that >50% of men with raised PSA do not have PCa and are 
unnecessarily subjected to transrectal ultrasound (TRUS) guided systematic biopsy of 
prostate gland (Martinez et al. 2013). In 2012, the U.S. Preventive Services Task Force 
(USPSTF) recommended against the routine use of PSA screening at any age. Clearly, 
PSA does not fulfill any currently acceptable standard of a screening test and a new 
screening test is needed. To meet this challenge, we propose a prostate cancer 
microparticle based test.  
Microparticles (MPs) are fragments of cells that are released by the prostate gland as the 
cells undergo division, necrosis, apoptosis, and/or exocytosis (Rak, 2013). Using a 
monoclonal antibody specific to the receptors expressed on prostate cancer we can 
identify prostate cancer microparticles (PCMP) and these novel markers may be used for 
diagnosis and monitoring of PCa. 
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3.2 Objective 
The objectives of this study were;  
1. To differentiate patients with prostate cancer from those with BPH or ‘no cancer’.  
2. To determine the difference in PCMP levels  in the two groups namely,  
a. Men with localized PCa  
b. Men with biopsy proven BPH and no evidence of PCa. 
3.3 Materials and Methods 
After obtaining the necessary ethical approval was obtained from Western University 
(Appendix 1), we analysed 405 plasma samples. 249 PCa plasma samples were obtained 
from Ontario Institute of Cancer Research (OICR) and 147 samples of patients with 
prostate biopsy proven BPH were obtained from Princess Margaret Hospital GU Tissue 
Bank (PMH). We also recruited 9 patients with BPH at London Heath Sciences (LHSC), 
these patients had a TRUS biopsy to rule out PCa and also underwent transurethral 
resection with histologically confirmed BPH. 
Collection of Samples 
Sample from Tumor Bank: The samples were obtained from the tumour banks in aliquots 
of 3-5 ml of frozen plasma. Services of an appropriate transportation company were 
engaged to ensure that the samples were transported frozen at -80 degrees Celsius. These 
samples were obtained from patients prior to definitive treatment for PCa. Each patient 
donated around 10-15ml of blood which was obtained in a 4.5 mL EDTA vacutainer 
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(Purple top tubes). The vacutainer was centrifuged at 2000 RCF for 20 min. This resulted 
in the blood separating into two distinct layers, a red layer (erythrocytes) and a yellow 
upper layer (platelet poor plasma-PPP). Using a plastic disposable Pasteur pipet, the PPP 
was transferred into tube for storage at -80 degree Celsius.  
Samples from London Health Sciences: Nine samples were obtained from patients 
undergoing transurethral resection of prostate (TURP). These patients were previously 
worked up for lower urinary tract symptoms and presence of PCa was ruled out by 
transrectal ultrasound guided biopsy. The final pathology report from the TURP 
specimen was consistent with histological diagnosis of BPH. Prior to surgery 10-15 ml of 
blood was drawn in a purple top tube and centrifuged at 2000 RCF for 20 min. This 
resulted in the blood separating into two distinct layers, a red layer (erythrocytes) and a 
yellow upper layer (platelet poor plasma-PPP). Using a plastic disposable Pasteur pipet, 
the PPP was transferred into tube for storage at -80 degree Celsius.  
Randomization and blinding 
All the samples were thawed and aliquoted again. The samples were randomized and 
numbered to blind the observer during analysis of samples. These randomized and 
relabelled samples were stored at -80 degree Celsius until they were used during the 
experiment. The master list was kept separately in the office of Dr. Hon Leong, PhD.  
Preparation of samples 
We prepared two mixtures of antibodies in two different tubes to be used in this 
experiment. We labeled one tube as ‘positive antibody’ and the second as ‘isotype 
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antibody’. Isotype antibodies were used as control for each sample as the florescence-
conjugated antibodies known to bind with trace amounts of nonspecific proteins and 
produce auto florescence. The use of isotype antibodies helped us in identifying this 
background noise. The numbers of events in the isotype sample were then subtracted 
from the counts observed in the sample, labeled as ‘positive antibody’. This methodology 
helped in eliminating the effect of this non specific binding. The positive antibody tube 
was used to prepare a mixture of antibodies namely PSMA-PE antibody (3/E7), Ghrelin 
peptide, GRPR antibody. Similarly we prepared a mixture of isotype controls for using 
mouse IgG-RPE antibody for PSMA, Ghrelin/LCE antibody for ghrelin and rabbit IgG 
antibody for GRPR for the tube labeled as isotype antibody. The concentration of PSMA-
PE antibody (3/E7) used was 408.42 µg/ml, the concentration of Ghrelin peptide used 
was 62.5mM and the concentration GRPR used was 0.5 µg/ml. The concentrations of 
isotype antibodies were matched.  
To simplify the process of conjugation of the antibodies we prepared two cocktails. The 
tube labeled positive contained; 24µL of GRPR, 24 µL of 2° antibody, 12 µL each of 
PSMA mAb and Ghrelin peptide. The total volume of this mixture was 72 µL. Similarly 
we used 24 µL of rabbit IgG antibody for GRPR, 24 µL of 2° antibody and 12 µL each of 
mouse IgG-RPE antibody for PSMA, Ghrelin/LCE antibody for Ghrelin. The total 
volume of this mixture was also 72 µL. This volume was enough to conduct the 
experiment on a batch of 10 samples at one time.  
We transferred 20 µL of platelet poor plasma (PPP) from a sample to two sterile 1.5 mL 
eppendorf tubes. The tubes were labeled as tube ‘+ve’ and ‘–ve’ and given a numbers xxx 
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according to previous randomization.  We added 6 µL from tube labeled ‘positive 
antibody’ to the tube labeled ‘+ve’ xxx and 6 µL from tube labeled ‘isotype antibody’ to 
the tube labeled ‘-ve’xxx.  
Both the tubes were mixed well and immediately incubate in the dark for 30 min. After 
incubation we added 600uL of sheath fluid (1X PBS, pH 7.4) using 1000 uL pipetman to 
each tube and vortexed.  
Analysis of samples on Flow cytometer 
The samples were analysed on A−50 Micro nanoscale flow cytometer (Apogee Flow 
Systems Inc.) to enumerate events. The optimization was performed using samples from 
healthy volunteers and patients with high volume/grade PCa. We used varying 
concentrations for antibodies during the optimization stage and chose the concentration 
which revealed the maximum discrimination in the two selected populations. We then 
selected our gates for calculation of the events. Each event seen on the histogram is a 
reflection of a single MP captured as a result of binding to a specific antibody. The 
location of each event on the histogram is a reflection of the characteristic of its 
florescence and size.  Apogee A-50 nanoscale flow cytometer has the capacity to 
discriminate events generated by submicron structures. We selected specific gates to 
capture a selected population of MP. These gates were created by drawing boundaries 
around the population of interest, which was identified during the optimization as most 
discriminatory between the two groups. Figure 10 illustrates the settings for the 
histograms. 
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We then analyzed our study samples and used the same settings (identified during 
optimization) throughout the study. The numbers of events per microliter were recorded 
for each sample.  The isotype controls were used to calculate the background activity of 
each sample. We subtracted the number of events in the isotype from the sample to 
calculate the ‘compensated’ number of microparticles events for each specimen.    
3.4 Statistical Analysis 
We used SPSS version 21.0 for statistical analysis. One-way ANOVA test (Ordinary) 
was used to compare the mean number of events in the two groups using. The confidence 
interval was set at 95% and the p-value of < 0.05 was considered significant.  
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PSMA-PE 
Small Angle  
Light Scatter (size)
Ghrelin-Cy5 
Long Angle  
Light Scatter (size) 
Figure 10. Histogram from Apogee A-50 nanoscale flow cytometer obtained 
from a patient plasma from group 1 representing patients with prostate cancer  
The top panel (A) represents all microparticle events analyzed according to 
size (long angle vs. small angle light scatter, Y vs. X axis respectively).  The 
bottom panel (B) represents those same events but analyzed for PSMA + 
Ghrelin, dual positive MP, On Y axis is Ghrelin-Cy5  and on X axis is 
PSMA-PE. 
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3.5 Results 
Four hundred and five randomized samples were analyzed. The patients were divided in 
two groups. Group 1 representing 249 patients with prostate cancer and Group 2 included 
156 patients with BPH.  
 In Group 1 (PCa), 65% patients were aged between 40-64 years (range 49-79 years). The 
mean PSA was 13.88 + 62.22 ng/mL (range 1.5 ng/mL to 541 ng/mL) and the median 
PSA was 7 ng/ml. The pathologic T stage of the tumors (Group 1) is shown in Table 4 
and the distribution of Gleason Score is shown in Table 5. In Group 2 (BPH), the mean 
age of patients was 64.5 + 6.19 years (range 49-79 years). All patients in Group 2 had 
biopsy proven BPH, the median size of the prostate gland was 67.5 grams calculated on 
trans-rectal ultrasound. The mean PSA was 10.07 + 5.82ng/mL and the median PSA was 
8.7 ng/ml. 
Group 1 contained 249 patients diagnosed with PCa. The mean number of PSMA 
positive events in this group was 160412 + 11480 events/µL. The mean number of PSMA 
and Ghrelin (dual positive events), PSMA and GRPR (dual positive events) and 
PSMA/Ghrelin/GRPR (triple positive events) is shown in Table 6. 
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pT Stage (n=164) Number of Patients (%) 
pT2a 38 (23.1) 
pT2b 16 (9.7) 
pT2c 39 (23.7) 
pT3a 46 (28) 
pT3b 23 (14) 
pTx 2 (1.2) 
Table 4. Distribution of Pathologic T stage in Group 1 
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Gleason Score (n=185) Number of Patients (%) 
6 53 (28.6) 
7 114 (61.6) 
8 5 (1.0) 
9 13 (7.0) 
Table 5. Distribution of Gleason Score in Group 1 
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Group 2 was comprised of 156 samples from patients with BPH. The mean number of 
PSMA positive events in this group was 186119 + 20231 events/mL.  The mean number 
of PSMA and Ghrelin, PSMA and GRPR (dual positive events) and PSMA and Ghrelin 
and GRPR (triple positive events) is shown in Table 7. A comparison of the mean 
number of MP events for each type of MP in the two groups is shown in Figure 12. 
We compared the number of events in the two groups using the one-way ANOVA 
(Ordinary) test to compare the means. The confidence interval was set at 95% and a p-
value of < 0.05 was considered significant. Table 8 shows the comparison of the number 
of microparticle events expressing various biomarkers in the two groups. This 
comparison is also shown in Figure 13. 
We did not find any significant differences in mean number of PSMA positive 
microparticle events, PSMA+GRPR or PSMA+Ghrelin dual positive microparticle 
events, or PSMA+Ghrelin+GRPR triple positive microparticle events.  
We also looked at the distribution of the number of MP subtypes in different subgroups 
of PSA and Gleason Score. Figure 16 and Figure 17 show the number of MP expressing 
various biomarkers in the three tiers of PSA levels i.e. < 4ng/ml, 4-10 ng/ml and 
>10ng/ml in Group 1 and Group 2. Figure 18 shows comparison of number of MP events 
expressing various biomarkers in the two groups stratified by levels of PSA. 
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PSMA 
 
+ve 
events/µL  
PSMA+GRPR 
 
Dual +ve 
events/µL  
PSMA+Ghrelin  
 
Dual +ve 
events/µL  
PSMA+GRPR+ 
Ghrelin 
Triple +ve 
events/µL  
Mean 160412 55177 56658 7909 
Median 99585 21144 38594 3163 
SEM 11480 5413 5376 696 
Table 6. Microparticle Events Expressing Various Biomarkers (Prostate Specific 
Membrane Antigen/PSMA, Gastrin-Releasing Peptide Receptor/GRPR, Ghrelin peptide 
ligand/Ghrelin) in Plasmas from Patients with Prostate Cancer (PCa, Group 1). N=249. 
The Mean, Median and Standard Error were calculated using SPSS version 21.0. 
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PSMA 
 
+ve 
events/µL 
PSMA+GRPR 
 
Dual +ve 
events/µL 
PSMA+Ghrelin 
 
Dual +ve 
events/µL 
PSMA+GRPR+ 
Ghrelin 
Triple +ve 
events/µL 
Mean 186119 45885 67284 8946 
Median 86155 17407 49973 2483 
SEM 20231 5549 5795 1142 
Table 7. Microparticles Events Expressing Various Biomarkers (Prostate Specific 
Membrane Antigen/PSMA, Gastrin-Releasing Peptide Receptor/GRPR, Ghrelin peptide 
ligand/Ghrelin) in Plasmas from Patients with Benign Prostatic Hyperplasia (BPH, Group 
2). N=156. The Mean, Median and Standard Error were calculated using SPSS version 
21.0. 
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Figure 11. Mean Concentration of MPs Expressing Various Biomarkers; PSMA, PSMA 
+ GRPR, PSMA + Ghrelin and PSMA + GRPR + Ghrelin in  Prostate Cancer Patient 
Plasmas (Blue, N=249) and BPH Patient Plasmas (Red, N=156).  One-way ANOVA 
(Ordinary) test was used to compare the means of the two groups.  
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Mean # events/µL Group 1 
   (n=249) 
Group 2        
(n=156) 
p-value 
PSMA +ve MPs 160412 + 11480 186119 + 20231 0.235 
PSMA+GRPR 
Dual +ve MPs 
55177 + 5413 45885 + 5549 0.254 
PSMA+Ghrelin 
Dual +ve MPs 
56658+ 5376 67284 + 5795 0.196 
PSMA+GRPR+Ghrelin 
Triple +ve MPs 
7990 + 696 8946 + 1142 0.411 
Table 8. Concentration of MPs Expressing Various Biomarkers in Prostate Cancer Patient 
Plasmas (Group 1) and BPH Patient Plasmas (Group 2).  One-way ANOVA (Ordinary) 
test was used for comparison using SPSS version 21.0.  
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Figure 12. Mean Concentration of MPs Expressing Various Combinations of Biomarkers 
in Prostate Cancer Patient Plasmas (N=72) Stratified into Three PSA Groups (PSA < 4 
ng/mL, 4-10 ng/mL and >10 ng/mL). 
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Figure 13. Mean Concentration of MPs Expressing Various Combinations of Biomarkers 
in BPH Patient Plasmas (N=143) stratified in Three PSA Groups (PSA < 4 ng/mL, 4-10 
ng/mL and >10 ng/mL). 
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We compared PSMA positive microparticle events, PSMA+GRPR or PSMA+Ghrelin 
dual positive microparticle events, and PSMA+Ghrelin+GRPR triple positive 
microparticle events to determine if this test was able to differentiate between the patients 
with cancer and BPH in any subgroup, stratified on the basis of PSA cutoff, but we did 
not find any statistically significant difference. Table 9, 10 and 11 shows the comparison 
in different in the different PSA tiers with BPH group. 
We also compared PSMA positive, PSMA+GRPR or PSMA+Ghrelin, dual positive, and 
PSMA+Ghrelin+GRPR triple positive microparticle events in patients with different 
Gleason score and BPH. We divided the patients with PCa in three groups comprising of 
patient plasma from Gleason score < 6, 7 and > 8. The main limitation of this comparison 
was the small number of patients in the subgroups. We found significantly higher number 
of PSMA+ Ghrelin dual positive in BPH group in comparison with all the subgroups of 
patients with PCa. This Gleason score wise comparison using various biomarkers with 
patient plasmas from BPH is shown in Figure 15. We also found a statistically 
significant difference in PSMA only positive MP events in the Gleason score 7 and >8 
compared with BPH but the association was opposite in these groups. PSMA only 
positive MP were significantly higher in BPH compared to Gleason score 7 (p=0.003) 
and significantly lower in BPH compared to Gleason score >8 (p=0.01). 
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Events/µL 
Group 1 
(n=9) 
Group 2 
(n=8) 
p-value and 
Confidence Interval 
PSMA 
+ve 
196346 + 38709 331700 + 113016 0.821 
(-157910 to 198622) 
PSMA+GRPR 
Dual +ve 
91438 + 29595 26933 + 7931 0.057 
(-252 to 98562) 
PSMA+Ghrelin 
Dual +ve 
31414 + 6241 88785 + 26352 0.998 
(-53758 to 53660) 
PSMA+GRPR+ 
Ghrelin 
Triple +ve 
13226 + 3707 4754 + 2229 0.233 
(-3909  to 15949) 
Table 9. Comparison of Concentration of MPs Expressing Various Biomarkers in 
Prostate Cancer Patient Plasmas (Group 1) and BPH Patient Plasmas (Group 2) for 
Patients with PSA < 4ng/mL.  One-way ANOVA (Ordinary) test was used for 
comparison.  
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Events/µL 
Group 1 
(n=49) 
Group 2 
(n=79) 
p-value and 
Confidence Interval 
PSMA 
+ve 
104401 + 33473 165908 + 21516 0.832 
(-152654 to 9476) 
PSMA+GRPR 
Dual +ve 
33435 + 6349 46502 + 7102 0.1033 
(-37699 to 3503) 
PSMA+Ghrelin 
Dual +ve 
-7339 + 31171 66945 + 5675 0.1037 
(-85615 to 8011) 
PSMA+GRPR+ 
Ghrelin 
Triple +ve 
5224 + 1163 9227+ 1422 0.3516 
(-6168 to 2204) 
Table 10.  Comparison of Concentration of MPs Expressing Various Biomarkers in 
Prostate Cancer Patient Plasmas (Group 1) and BPH Patient Plasmas (Group 2) for 
Patients with between PSA 4 to 10 ng/mL.  One-way ANOVA (Ordinary) test was used 
for comparison.  
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Events/µL 
Group 1 
(n=22) 
Group 2 
(n=56) 
p-value and 
Confidence Interval 
PSMA 
+ve 
141613 + 34053 218981 + 42493 0.537 
(-144092 to 75338) 
PSMA+GRPR 
Dual +ve 
26810 + 11593 54918 + 11170 0.3085 
( -45366 to 14422) 
PSMA+Ghrelin 
Dual +ve 
32318 + 6917 74733 + 12894 0.9589 
(-31844 to 33554) 
PSMA+GRPR+ 
Ghrelin 
Triple +ve 
3724 + 1053 10646 + 2338 0.2494 
(-9429 to 2465) 
Table 11. Comparison of Concentration of MPs Expressing Various Biomarkers in 
Prostate Cancer Patient Plasmas (Group 1) and BPH Patient Plasmas (Group 2) for 
Patients with between PSA >10 ng/mL.  One-way ANOVA (Ordinary) test was used for 
comparison.  
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Figure 14.Comparison of Mean Concentration of MPs Expressing Various 
Combinations of Biomarkers in Prostate Cancer Patient Plasmas (Blue, N=74) and 
BPH Patient Plasmas (Red, N=143) stratified in Three PSA Groups (PSA < 4 ng/mL, 
4-10 ng/mL and >10 ng/mL). One-way ANOVA (Ordinary) test was used to compare 
the means of the two groups.  
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Figure 15. Comparison of Various Combinations of Biomarkers in Prostate 
Cancer Patient Plasmas with Gleason Score 6, 7 and  > 8 and BPH Patient 
Plasmas. One-way ANOVA (Ordinary) test was used to compare the means 
of the two groups.   * denotes statistical significance.  
 
 81 
 
 
3.6 Discussion 
The concerted efforts to develop a biomarker for screening of prostate cancer (PCa) have 
been significantly accelerated after the publication of recent reports that have highlighted 
the potential harms of prostate specific antigen (PSA) based screening (Andriole et al. 
2009). In this study we investigated a blood test based on enumeration of microparticle 
(MP) as a biomarker to identify PCa. MPs are defined as plasma membrane derived 
structures of a diameter of less than 1000nm. They are released from the cell upon 
activation, death, apoptosis or malignant transformation and inherit surface receptors 
from their cell of origin (Rak, 2013).  Using monoclonal antibodies (mAb) specific for 
these antigens it may be possible to identify them. Surgical pathologists have used this 
technique to interpret specimens from metastatic sites with unknown primary lesion. 
mAb against cell specific receptors are used identify the primary site of origin of these 
metastatic lesions. Modified monoclonal antibodies have also been used as imaging 
agents and tagged with therapeutic arsenal to deliver targeted therapy (Deckert et al. 
2009).   
In this study we investigated four biomarkers to differentiate patients with PCa from 
benign prostatic hypertrophy (BPH). We selected mAb specific for prostate specific 
membrane antigen (PSMA) and gastrin releasing peptide receptor (GRPR). We also 
selected ghrelin peptide, a ligand for growth hormone secretagogue receptor (GHSR). 
The four biomarkers were PSMA alone and a combination of PSMA with GRPR and or 
Ghrelin. 
 82 
 
Sokoloff et al. have demonstrated that PSMA is expressed more than 100 fold higher in 
prostate cancer cells in comparison to normal prostate cells (Sokoloff et al. 2000). PSMA 
based imaging (ProstaScint scan, Cytogen, Philadelphia, PA) for metastatic evaluation of 
PCa is US-FDA approved, however it has not been shown to be very effective (Rosenthal 
et al. 2001). The limited success of ProstaScint scan is mainly attributed to the long 
scanning time. The PSMA antibody used in this imaging modality was required to be 
injected several days before the planned imaging, thus making it less attractive for 
practical clinical use (Foss et al. 2012). A recent review analyzing published literature 
investigating PSMA in the last 20 years reveals robust research and an optimistic future 
for PSMA based treatment for castrate resistant PCa (Ritasu et al. 2013). In our study 
PSMA positive MP events were non-significantly elevated in the BPH group (p=0.235). 
The subgroup analysis according to the PSA tiers of <4 ng/ml, 4-10 ng/ml and >10 ng/ml 
also did not reveal any significant difference in the PSMA positive MP counts among the 
two groups. However, PSMA positive MP were significantly higher in BPH compared to 
Gleason score 7 (p=0.003) and significantly lower in BPH compared to Gleason score >8 
(p=0.01). As the number of patients in Gleason >8 category was small (n=18) we are 
unable to draw any meaningful conclusion. 
PSMA + GRPR, dual positive MP events were also investigated as a potential biomarker. 
Beer et al. in his study had demonstrated that two third of primary prostate cancer stain 
positively with GRPR (Beer et al. 2012). In another study looking at co-expression of 
PSMA and GRPR found the all cases of metastatic PCa stained positively for PSMA and 
87% also co-stained with GRPR (Ananias et al. 2009). In our study we found statistically 
insignificant difference in PSMA+GRPR, dual positive MP in the PCa group (p=0.254). 
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In the sub group analysis we found this difference to approach statistical significance (p= 
0.057) in the sub group of patient plasma with PSA of < 4ng/ml. This finding needs 
further investigation as the number of patients both the groups was very small ( n=8 vs. 
n=9).  
In our pilot study we found PSMA + Ghrelin, positive dual positive MP events to 
discriminate patients with PCa (Siddiqui et al. 2013). On contrary to our expectation in 
this study we found this biomarker to be elevated in patients with BPH. Overall the 
difference in PSMA + Ghrelin, dual positive MP events was not statistically significant 
(p=0.998). In subgroup analysis PSMA + Ghrelin, dual positive MP events were 
significantly higher in BPH group compared to all categories of Gleason score. This find 
may have been due to the fact that patients in BPH group had a higher median PSA 
compared to PCa group (7ng/ml vs. 8.7ng/ml). But when we controlled for PSA, the 
subgroup analysis did not show any significant difference. The other theoretical 
possibility may be that patients in the BPH group harbored an occult focus of PCa.  
PSMA + GRPR + Ghrelin, triple positive MP was evaluated as the fourth biomarker in 
this study. We found this to be also non discriminatory (7990 + 696 vs. 8946 + 1142, 
p=0.411). Thus all four biomarkers studied in were not able to discriminate patients with 
PCa from BPH.  
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3.7 Conclusions 
Prostate cancer MP can be enumerated by nanoscale flow cytometer proving the utility of 
Apogee A-50 flow cytometer to detect MP. This enhances our capacity of analyze MP in 
a high throughput and multi-parametric manner.  
Although, all four biomarker were not able to discriminate patients with PCa from patient 
with BPH but in patients with PSA <4ng/ml, PSMA+GRPR dual positive MP showed a 
trend toward statistical significance in discrimination between the two groups. Further 
exploration of this biomarker with larger numbers may help in identifying a biomarker 
which can help discriminate patients with PSA in this range. The subgroup analysis 
comparing Gleason score and BPH showed that PSMA + Ghrelin, dual positive MP was 
higher in the BPH.  
A blood test based on enumeration of MP may hold the promise as it has the potential to 
measure prostate cancer fragments continuously released from cancer cells. When 
perfected this test may be used as a fluid biopsy to continually sample the tumor. 
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4 Chapter 4 
4.1 General Discussion 
Synchronous improvement in quality of care, dissemination of refined surgical technique, 
improvement in the radiation technology along with the early stage of PCa at presentation 
has contributed to better outcomes of prostate cancer. However, we now see a plateau in 
the mortality curves (Otis et al. 2012). The plateau reflects that we are not diagnosing all 
patients and that treatment is still not perfect. We know that PSA is not a true tumor 
marker for prostate cancer and this surrogate marker may be raised in a number of non-
malignant conditions. Transrectal ultrasound (TRUS) guided prostate biopsy is the corner 
stone of management and is the most common modality to obtain a histological diagnosis 
which is a mandatory investigation for definitive diagnosis. A standard 8-12 core biopsy 
is reported to have a positive yield of around 50% (Lawrentschuk et al. 2009).  Therefore, 
for the majority of men a biopsy recommended due to an elevated PSA fail to reveal the 
diagnosis of PCa and often they are undergo more than one biopsy procedure (Shinohara 
et al. 2014). This potentially exposes them to the complications of the procedure and is a 
cause of persistent anxiety. Ideally, we need a cost effective test that can confidently 
diagnose cancer and this test should be able to predict its clinical course. This test should 
preferably also avoid the need for biopsy or recommend biopsy for a very select 
population. To meet the challenge of a screening test superior to PSA, we attempted to 
explore a prostate microparticle-based “fluid biopsy” which could continually sample the 
prostate gland and its primary tumor to gain insight regarding the biology of these tissues. 
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MP released into blood, urine, and body fluids offers a novel opportunity to sample the 
biological information from the mutant cancer cell along with the normal stromal cells. 
This MP based sampling has the potential to be superior to conventional 
histopathological assessment as this fluid biopsy may be able to capture information not 
limited by the anatomical boundaries of the pathology slide and provide a holistic view 
regardless of the regional differences observed in a tumor effected prostate gland 
(Heppner et al. 1984).  
Microparticles by our definition exhibit a diameter smaller than one micron and are 
manifest as fragments released from the cancer cell's surface. Our laboratory has 
validated the presence of MP by atomic force microscopy and have also analyzed them 
using flow cytometry (Leong et al. 2011). These MP retain the surface receptors present 
on the cells of origin. The significance of this in oncogenesis is still not determined but 
this property makes them potentially useful as disease biomarkers. We used the Apogee® 
A-50 nanoscale flow cytometer which has three lasers and is capable of recording dual 
and triple florescence positive events.  Our laboratory was the first one to acquire this 
technology in North America and is still among the few in Canada to have the capacity to 
use the A-50 micro nanoscale flow cytometer. 
We selected PSMA, GRPR and GHS receptor as these are surface receptors documented 
to be present on prostate cancer cells. It has been demonstrated that PSMA is expressed 
more than 100 fold higher in prostate cancer cells in comparison to normal prostate cells 
(Sokoloff et al. 2000). This led to development of PSMA antibodies which selectively 
target prostate cancer cells both at the primary site and at the site of metastasis. In a phase 
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1 trial, radio therapeutic agent Lutetium-177 was tagged to the PSMA antibody (J591) for 
treatment of metastatic lesions of castrate resistant prostate cancer with acceptable 
toxicity (Bunder et al. 2005). In a phase 2 trial, 60% PSA response was observed in 
patients treated with PSMA based antibody (Tagawa et al. 2008). A query for “PSMA” 
and “prostate cancer” reveals 14 current clinical trials (http://www.clinicaltrials.gov) 
exploring the role of PSMA in prostate cancer. The initial interest in PSMA antibody was 
for its potential role in imaging for prostate cancer however, the downside to antibody-
based imaging is the long time required for the antibody to clear from non-target tissues. 
This means that the antibody should be injected several days before the planned imaging, 
making it less attractive for practical clinical use (Foss et al. 2012).  
We explored the possibility of PSMA expression on MPs. In the pilot study we found that 
PSMA positive MPs can be enumerated using Apogee® A-50 nanoscale flow cytometer. 
In our pilot study we also found a stronger expression of PSMA positive MP in the 
patients with PCa in comparison with healthy volunteers and patients with BPH. In this 
study, the majority of samples in the control group were obtained from healthy volunteers 
and only 9 patients with BPH were included. The healthy volunteers in this study were 
aged younger than 35 years and did not have any history of cancer.  All groups did 
express PSMA positive events and this showed that PSMA positivity is not exclusive for 
prostate cancer. In our study, we were able to enumerate PSMA positive MPs but found 
statistically insignificant differences in MPs enumerated in the two groups. In contrary to 
our expectation we found a trend towards higher number of events in patients with BPH 
compared to PCa. We postulated that looking for co-expression of more than one 
biomarker would increase the specificity of prostate cancer specific biomarkers. We used 
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PSMA as our prostate-specific biomarker, and GRPR antibody and Ghrelin peptide 
(ligand) as our cancer-specific biomarkers.  Previous work in our laboratory had earlier 
confirmed that fluorescein labeled Ghrelin is over expressed in PCa compared to normal 
prostate (Lu et al. 2012). This study looked at PC3 and LNCaP cell lines along with 
specimens obtained from radical prostatectomy and concluded that this Ghrelin analog 
could be used as an imaging probe for PCa. In our pilot study with PSMA and Ghrelin 
dual positive markers we found this test to successfully discriminate PCa from the control 
but in our main study, we found that PSMA+Ghrelin dual positive MP events were 
higher in the BPH group compared to the cancer group (67284 + 5795 vs. 56658 + 5376, 
p=0.196).  
This was an unexpected finding as based on our pilot study we anticipated this to be the 
contrary.  The possible reasons for this difference in expected vs. observed maybe due to 
the fact that in our pilot study we compared patients with prostate cancer with mainly 
healthy controls and not BPH which is a benign tumor and may actually have over 
expression of PSMA. Due to the small number of patients with BPH in the pilot study 
this observation could have been masked. The patients in the BPH group also had a 
higher median PSA as compared to the cancer group, 8.7ng/ml vs.7 ng/ml. Although all 
the men in the BPH group had a TRUS biopsy to rule out prostate cancer, they were to 
begin with, at a high risk of having cancer which had initiated the biopsy. The risk of 
having a high volume PCa was ruled out with the prostate biopsy but we also understand 
that TRUS biopsy has its limitations and it is even possible that some of the patients in 
the BPH group actually had a focus of cancer which was missed at the biopsy.  These are 
the inherent limitations of our control population. We designed this study to compare the 
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utility of these markers for distinguishing patients with prostate cancer from those with 
no cancer. This clinical equipoise is present in men who are recommended a biopsy 
hence we chose this control. This selection was made after we had documented in our 
pilot study that the MP are more abundant in the prostate cancer patients compared with 
healthy controls. We now desired to reproduce the results in a large number of samples 
from the patients who do not have prostate cancer and were able to have access to 
specimens from a bio bank which stored such samples. We presumed that this age and 
gender matched population would be an ideal control for the overall objective of the 
study. In our study we also noticed a large standard deviation in the number of events. 
This could mean that either the test fails to identify the MP or our group of patients in the 
control group is very heterogeneous mixture.  
We also used an additional third marker, GRPR for this experiment and enumerated 
PSMA and GRPR positive MP. We also used a combination of all three makers to 
identify MP which express all three surface antigens. This strategy was designed to 
further enhance the specificity of the test for enumeration of PCMP. Enhanced GRPR 
expression has previously been reported on PCa cells in vitro (Bologna et al. 1989). 
GRPR expression was further confirmed by studies which demonstrated growth of 
prostate cancer cells stimulated by the gastrin releasing peptide and inhibited by 
antagonists of GRP (Milovanovic et al. 1992). Another study found co-expression of 
GRPR and PSMA in both nodal and bony metastatic lesions of PCa (Ananias et al. 
2009). Similar expression was also demonstrated in primary prostate carcinomas (Beer et 
al. 2012). 
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In our study we enumerated PSMA and GRPR, dual positive MP and PSMA, Ghrelin and 
GRPR, triple positive MP and did not find any significant difference in the number of 
PSMA and GRPR dual positive (55177 + 5413 vs.45885 + 5549, p=0.254) and PSMA 
and GRPR and Ghrelin triple positive markers (7990 + 696 vs. 8946 + 1142, p=0.411) in 
the two groups. Thus this combination was also not able to discriminate patients with 
PCa from BPH.   
When we controlled for PSA and divided our patients in three groups i.e. PSA <4 ng/mL, 
4 to 10 ng/mL and >10 ng/mL and compared the number of MP events in the two groups, 
we did not find any statistically significant difference. However, when we compared the 
number of MP events for various biomarkers expressed in three different histological 
grades (Gleason scores 6, 7 and > 8) with patient plasma from Group 2 (BPH), a 
statistically significant difference in MP expressing PSMA and Ghrelin dual positive 
events was seen in Gleason score 6 and 7 (p=0.001). Similarly a statistically significant 
difference was also observed in the number of MP expressing PSMA only, in the Gleason 
score >8 compared with BPH (p=0.01).   The higher number of PSMA and Ghrelin, dual 
positive events in the BPH group was in contrary to our expectation. We anticipated a 
stronger expression of this biomarker in patient plasma with PCa. However the small 
sample size in this subgroup and the imbalanced groups used for comparison may have 
accounted for this statistical significance.  
4.1  Conclusion 
Our blood test based on PSMA, Ghrelin peptide ligand and GRPR has not been able to 
successfully differentiate patients with prostate cancer from those with BPH. However, 
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we have been able to enumerate microparticle expressing single, dual or triple positive 
events. This proves the utility of flow cytometer to detect MP in a high throughput and 
multiparametric manner. A blood test based on enumeration of MP holds the promise as 
it has the potential to measure prostate cancer fragments continuously released from 
cancer cells. When perfected this test may be used as a fluid biopsy to continually sample 
the tumor. 
4.2 Future Directions 
Our laboratory is currently investigating other biomarkers like prostate stem cell antigen 
(PSCA), TMPRSS2, AMACR etc. We plan to analyze PSMA + GRPR dual positive MP 
for patients with BPH and PCa having a PSA < 4 ng/ml. In this regard we have identified 
a source of patient plasmas with BPH and PSA of < 4ng/ml. Increasing the power of 
study to assess this biomarker may reveal interesting results. We are designing a study to 
explore PSMA + Ghrelin, dual positive MP as a biomarker for BPH. In collaboration 
with London bio-bank we are recruiting patients ahead of TRUS biopsy.  These patients 
will also have serial blood samples. The longer follow-up will significantly strengthen the 
control group for future experiments.   
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